A defined intake
A primary sequence and a set of product targets — concentration, presentation, device and the constraints the programme already carries. No prior screening campaign is required.
For partners
Built for teams that have to defend the decision later.
A partner should not have to spend two to three development quarters and grams of precious drug substance to discover which excipient system its molecule actually wants.
The engagement is deliberately narrow: a defined intake, a fixed output shape, and a design space your programme can keep referring back to.
Sequence-only intakeOne coherent datasetFits existing CMC workflow
How we work
A narrow engagement, on purpose.
Predictable in shape, so it can be planned into a programme rather than negotiated per molecule.
A fixed shape of work
The design space is explored computationally, then reduced to a rank-ordered, fully specified candidate set with bench-level SOPs. The output shape does not change between programmes.
A deliberate design space
Because the space is defined rather than sampled, later comparability exercises, scale-up and lifecycle changes rest on one coherent body of evidence.
A confirmatory bench plan
Your laboratory runs a focused confirmatory exercise against the ranked list, so FTE time and analytical load land where they change a decision.
Material discipline
Purified drug substance is usually the scarcest and most expensive input at early stage. Concentrating screening on a prioritized set is how that input is protected.
Your molecule stays yours
Sequences and product targets are partner material. Engagement terms, confidentiality and data handling are agreed in writing before any intake.
Business impact
The benefit shows up in three places.
Speed, cost, and the quality of the knowledge your programme carries forward.
Speed
Weeks rather than quarters.
A defensible, ranked formulation strategy is available in weeks rather than quarters, which pulls in the timing of tox lots, stability starts, first-in-human enabling material, and eventually CMC sections of regulatory filings.
- Tox lots scheduled earlier
- Stability starts brought forward
- First-in-human enabling material unblocked
- CMC sections written against a defined design space
Cost
A prioritized set, not a broad matrix.
Screening effort is concentrated on a prioritized set of conditions instead of a broad, unguided matrix. This reduces FTE time, analytical load, and the quantity of purified drug substance consumed — usually the scarcest and most expensive input at early stage.
- Less FTE time at the bench
- Lower analytical load
- Less purified drug substance consumed
- Effort spent confirming, not searching
Efficiency and knowledge quality
One coherent dataset, not scattered reports.
The partner receives a single, structured, statistically coherent dataset with confidence for every candidate, rather than a series of disconnected screening reports. The design space is defined deliberately, which strengthens later comparability, scale-up and lifecycle changes.
- Confidence attached to every candidate
- One structured dataset, not scattered reports
- A deliberately defined design space
- Stronger comparability, scale-up and lifecycle changes
Programme timing
What moves when the strategy arrives in weeks.
A defensible, ranked formulation strategy available in weeks rather than quarters pulls several downstream dates with it.
- Tox lotsScheduled against a ranked formulation strategy instead of waiting on one.
- Stability startsBrought forward, because the candidate set exists earlier.
- FIH enabling materialUnblocked sooner, with the excipient system already defensible.
- CMC sectionsWritten against a deliberately defined design space.
For partners
What development teams ask us.
Fit, intake, confidentiality, and working alongside your CDMO or CRO.
How does this fit an existing development plan?
It sits in front of formulation screening. Instead of a broad, unguided matrix, the laboratory receives a rank-ordered, fully specified candidate set with SOPs, and runs a focused confirmatory exercise. Downstream activities — tox lots, stability starts, first-in-human enabling material — can then be scheduled against a defensible strategy rather than waiting for one to emerge.
What do you need from our team?
A primary sequence and a set of product targets. Where a programme already carries constraints — a device, a fill volume, a platform buffer — those are part of the targets and shape the ranking.
What do we receive that a screening CRO would not give us?
A single, structured, statistically coherent dataset with confidence attached to every candidate, rather than a series of disconnected screening reports — and a design space that was defined deliberately, which is what later comparability, scale-up and lifecycle changes depend on.
How is confidentiality handled?
Sequences and product targets are partner material. Confidentiality, data handling and IP terms are agreed in writing before intake. If your organisation has a preferred agreement, we will work from it.
Can you work alongside our CDMO or CRO?
Yes. The deliverable is written to be executed by whoever runs the bench — an internal group, a CDMO or a CRO. The SOPs are at bench level for exactly that reason.
Want to see it against one of your molecules?
Send a primary sequence and your product targets under your own confidentiality terms. We will come back with a rank-ordered candidate set and the SOPs to confirm it.